Notably, hypophysitis is more commonly linked to cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, with an incidence of approximately 10%, whereas PD-1 inhibitors like pembrolizumab have a reported incidence of less than 1% [1]. Here, PDCD1 is linked to hypophysitis.